LAUSR

About LAUSR
Donate
Contact Us

Follow us:

You are not signed in:

Sign Up!


   Articles with "jak inhibitor" as a keyword



The clinical dilemma of JAK inhibitor failure in myelofibrosis: Predictive characteristics and outcomes

Sign Up to like & get
recommendations! Published in 2022 at "Cancer"

DOI: 10.1002/cncr.34222

Abstract: Two Janus‐associated kinase inhibitors (JAKi) (initially ruxolitinib and, more recently, fedratinib) have been approved as treatment options for patients who have intermediate‐risk and high‐risk myelofibrosis (MF), with pivotal trials demonstrating improvements in spleen volume, disease… read more here.

Keywords: clinical dilemma; jaki; inhibitor; myelofibrosis ... See more keywords

Momelotinib versus Continued Ruxolitinib or Best Available Therapy in JAK Inhibitor-Experienced Patients with Myelofibrosis and Anemia: Subgroup Analysis of SIMPLIFY-2

Sign Up to like & get
recommendations! Published in 2024 at "Advances in Therapy"

DOI: 10.1007/s12325-024-02928-4

Abstract: Some Janus kinase (JAK) inhibitors such as ruxolitinib and fedratinib do not address and may worsen anemia in patients with myelofibrosis. In these cases, the JAK inhibitor may be continued at a reduced dose in… read more here.

Keywords: momelotinib; inhibitor; anemia; blood ... See more keywords

Population Pharmacokinetic Analysis of Itacitinib, a Selective JAK-1 Inhibitor

Sign Up to like & get
recommendations! Published in 2019 at "Biology of Blood and Marrow Transplantation"

DOI: 10.1016/j.bbmt.2018.12.256

Abstract: Statement of Purpose, Innovation, or Hypothesis Itacitinib is a JAK-1 inhibitor currently in phase III development for the treatment of acute and chronic graft versus host disease (GVHD) in combination with corticosteroids. Itacitinib is primarily… read more here.

Keywords: pharmacokinetic analysis; population; itacitinib; population pharmacokinetic ... See more keywords

Pacritinib protects dendritic cells more efficiently than ruxolitinib.

Sign Up to like & get
recommendations! Published in 2021 at "Experimental hematology"

DOI: 10.1016/j.exphem.2021.06.004

Abstract: Targeting Januskinase (JAK) has revolutionized the treatment of myeloproliferative neoplasms. The JAK inhibitor ruxolitinib improved the outcome and quality of life of patients dramatically at the cost of increased risk of infections. As previously shown,… read more here.

Keywords: pacritinib; ruxolitinib pacritinib; jak inhibitor; dendritic cells ... See more keywords

Treatment of rats with the JAK-2 inhibitor fedratinib does not lead to experimental Wernicke’s encephalopathy

Sign Up to like & get
recommendations! Published in 2017 at "Neuroscience Letters"

DOI: 10.1016/j.neulet.2017.01.041

Abstract: Recent clinical trials suggest that patients with myelofibrosis can develop Wernicke's encephalopathy (WE) when treated with fedratinib, a specific Janus kinase-2 (JAK-2) inhibitor. To investigate this issue, we have examined (1) if fedratinib can produce… read more here.

Keywords: inhibitor; jak inhibitor; treatment; fedratinib lead ... See more keywords

Discovery and Characterization of the Topical Soft JAK Inhibitor CEE321 for Atopic Dermatitis.

Sign Up to like & get
recommendations! Published in 2023 at "Journal of medicinal chemistry"

DOI: 10.1021/acs.jmedchem.2c01977

Abstract: The JAK kinases JAK1, JAK2, JAK3, and TYK2 play key roles in cytokine signaling. Activation of the JAK/STAT pathways is linked to many diseases involving the immune system, including atopic dermatitis. As systemic JAK inhibitor… read more here.

Keywords: atopic dermatitis; jak inhibitor; cee321; jak ... See more keywords

Calreticulin mutant mice develop essential thrombocythemia that is ameliorated by the JAK inhibitor ruxolitinib

Sign Up to like & get
recommendations! Published in 2017 at "Leukemia"

DOI: 10.1038/leu.2016.308

Abstract: Mutations of calreticulin (CALR) are detected in 25–30% of patients with essential thrombocythemia (ET) or primary myelofibrosis and cause frameshifts that result in proteins with a novel C-terminal. We demonstrate that CALR mutations activated signal… read more here.

Keywords: inhibitor ruxolitinib; jak inhibitor; mice; calr ... See more keywords

Characteristics and predictive values of super-responders in alopecia areata under tofacitinib treatment: A single-center retrospective study.

Sign Up to like & get
recommendations! Published in 2025 at "Clinical and experimental dermatology"

DOI: 10.1093/ced/llaf131

Abstract: BACKGROUND Alopecia areata (AA) is an autoimmune disorder characterized by non-scarring hair loss, significantly impacting patients' quality of life. Rapid hair regrowth is the primary goal of treatment, particularly for super-responders (SRs), who demonstrate remarkable… read more here.

Keywords: treatment; single center; alopecia areata; super responders ... See more keywords

DOP053 Efficacy of appendectomy in inducing remission in moderate-to-severe ulcerative colitis: preliminary one year results of a multicentre prospective cohort study (COSTA)

Sign Up to like & get
recommendations! Published in 2025 at "Journal of Crohn's and Colitis"

DOI: 10.1093/ecco-jcc/jjae190.0092

Abstract: This study aimed to evaluate the efficacy of appendectomy in inducing remission in patients with moderately to severely active ulcerative colitis (UC), despite biological or small molecule therapy. This multicentre, prospective cohort study included patients… read more here.

Keywords: colitis; therapy; group; remission ... See more keywords

The pan‐JAK inhibitor delgocitinib in a cream formulation demonstrates dose response in chronic hand eczema in a 16‐week randomized phase IIb trial *

Sign Up to like & get
recommendations! Published in 2022 at "British Journal of Dermatology"

DOI: 10.1111/bjd.21037

Abstract: Chronic hand eczema (CHE) is a burdensome disease, and new well‐documented, safe and efficacious treatments are warranted. In a recent CHE phase IIa trial, the pan‐Janus kinase (JAK) inhibitor delgocitinib in an ointment formulation was… read more here.

Keywords: chronic hand; hand eczema; jak inhibitor; inhibitor delgocitinib ... See more keywords

JAK inhibitor ruxolitinib inhibits the expression of cytokines characteristic of cutaneous lupus erythematosus

Sign Up to like & get
recommendations! Published in 2017 at "Experimental Dermatology"

DOI: 10.1111/exd.13253

Abstract: This study was stimulated by the clinical observation of a rapid response of a chilblain lupus patient to treatment with JAK1/2‐kinase inhibitor ruxolitinib. We investigated the in vivo expression of phospho‐JAK2 in CLE skin samples… read more here.

Keywords: inhibitor ruxolitinib; ruxolitinib; jak inhibitor; ruxolitinib inhibits ... See more keywords